Clinical Trials Browser

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colonic Neoplasms, Colorectal Neoplasms

Lung Neoplasms, Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Fatigue, Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Mesothelioma, Malignant, Anus Neoplasms, Sarcoma, Colorectal Neoplasms, Small Cell Lung Carcinoma

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Neoplasm Metastasis, Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Neoplasm Metastasis, Colorectal Neoplasms

Neoplasm Metastasis, Colorectal Neoplasms

Clinical Trials

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

PARERE

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

x-МАР

SOREGATT

CARE

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

Efficacy of Ginseng for Patients on Regorafenib

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

REFIT-MSS

VIVA

Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC

A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

RE-ARRANGE

Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

PARICCA

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer

TEXCAN

Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer

Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers

REFRAME

PREVIUM